This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F13%3A10209746%21RIV14-GA0-11130___/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n21http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F13%3A10209746%21RIV14-GA0-11130___
rdf:type
n8:Vysledek skos:Concept
rdfs:seeAlso
http://www.spandidos-publications.com/10.3892/or.2013.2389
dcterms:description
Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 mu M) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 mu M) to 106 mu M with the highest applied concentration of sarcosine (1,500 mu M). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at P<0.001) and between DMPD and ABST (r=-0.64 at P<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at P<0.001) was observed. Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 mu M) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 mu M) to 106 mu M with the highest applied concentration of sarcosine (1,500 mu M). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at P<0.001) and between DMPD and ABST (r=-0.64 at P<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at P<0.001) was observed.
dcterms:title
Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line
skos:prefLabel
Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line
skos:notation
RIV/00216208:11130/13:10209746!RIV14-GA0-11130___
n8:predkladatel
n9:orjk%3A11130
n3:aktivita
n14:I n14:P
n3:aktivity
I, P(ED1.1.00/02.0068), P(GAP102/11/1068), P(GAP301/10/0356)
n3:cisloPeriodika
6
n3:dodaniDat
n4:2014
n3:domaciTvurceVysledku
n17:9974687 n17:5742587
n3:druhVysledku
n19:J
n3:duvernostUdaju
n21:S
n3:entitaPredkladatele
n20:predkladatel
n3:idSjednocenehoVysledku
71715
n3:idVysledku
RIV/00216208:11130/13:10209746
n3:jazykVysledku
n12:eng
n3:klicovaSlova
Brdicka reaction; ion-exchange chromatography; chip electrophoresis; antioxidant activity; metallothionein; prostate cancer; sarcosine
n3:klicoveSlovo
n6:chip%20electrophoresis n6:Brdicka%20reaction n6:metallothionein n6:antioxidant%20activity n6:sarcosine n6:ion-exchange%20chromatography n6:prostate%20cancer
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[9AFE6ECA326B]
n3:nazevZdroje
Oncology Reports
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
14
n3:projekt
n18:GAP102%2F11%2F1068 n18:GAP301%2F10%2F0356 n18:ED1.1.00%2F02.0068
n3:rokUplatneniVysledku
n4:2013
n3:svazekPeriodika
29
n3:tvurceVysledku
Skalickova, Sylvie Trnková, Libuše Kizek, Rene Eckschlager, Tomáš Sztalmachova, Marketa Zitka, Ondrej Sochor, Jiří Adam, Vojtěch Kruseová, Jarmila Hubalek, Jaromír Cernei, Natalia Gumulec, Jaromír Masarik, Michal Rodrigo, Miguel Angel Merlos
n3:wos
000319232800052
s:issn
1021-335X
s:numberOfPages
8
n15:doi
10.3892/or.2013.2389
n10:organizacniJednotka
11130